Caroline Fortier

Esperas Pharma, Inc. manufactures and develops pharmaceutical products. The firm is created to develop one compound to proof-of-concept. It plans to develop, to proof-of-concept, a compound originally discovered through one of Lilly’s research and development programs, with the potential to treat certain types of cancers including triple negative breast cancer. The company was founded in 2015 and is headquartered in Montreal, Canada.

GLWL Research, Inc. is a medical research laboratory. It develops and proofs compounds for treatment of diabetes where it has developed an investigational compound known as GLWL-01 to treat type-2 diabetes. The company is headquartered in Montreal, Canada.

AurKa Pharma, Inc. develops medication for cancer treatment. The company was founded by Caroline Fortier and is headquartered in Montreal, Canada.

Société Générale de Promotion & de Financement Immobiliers SA provides real estate services. It offers renting, buying, selling and appraising real estate. The company is headquartered in Courbevoie, France.

Part of Société Générale SA, Sogeprom Partenaires SAS is a French real estate services company. The company is based in Courbevoie, France. The company was founded in 1994. The CEO is Caroline Fortier.

PRCL Research Inc. is a special purpose company created to develop one compound to proof-of-concept. It engages in the development of a clinical candidate against a novel target for the treatment of chronic inflammatory diseases. The company was founded on October 4, 2013 and is headquartered in Montreal, Canada.

Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population. Genizon has one of the largest GWAS programs worldwide, addressing many common diseases and traits. Several of these have been successfully completed, generating comprehensive maps of interacting genes, biomarkers and biological disease pathways (known as GeneMaps), providing strong validation of the power of the Company's discovery platform. Genizon has out-licensed some of the therapeutic and diagnostic rights to GeneMaps for Crohn's disease (to Genentech) and attention deficit hyperactivity disorder, endometriosis and Alzheimer's disease (disease-state diagnostic rights to Pfizer). GeneMaps have also been generated from GWAS in schizophrenia, psoriasis and longevity. GWAS are in progress for rheumatoid arthritis, Alzheimer's disease, and coronary heart disease and its precursors, obesity, type II diabetes, dyslipidemia and hypertension (collectively metabolic syndrome). Genizon's technology platform and discoveries can complement current R&D programs by using human genetics to significantly enhance research and by adding value at multiple stages of the drug development process. Genizon is continually developing and enhancing its gene and biomarker discovery platform. For example, the company is assessing the role of copy number variations (CNVs) in diseases- applying new methods to ongoing large-scale GWAS in rheumatoid arthritis and metabolic syndrome, and retrospectively to previous studies. Genizon also leverages its platform and expertise by offering high throughput, high quality SNP genotyping, statistical genetics, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry.